TORONTO, Jan. 9, 2013 /PRNewswire/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial
manufacturing services to the global pharmaceutical industry, today
announced that Aqeel Fatmi, Ph.D., was appointed as Executive Vice
President, Global Research & Development of the proprietary products
and technology business as well as Patheon's Chief Scientific Officer.
"I am extremely pleased to be formally welcoming Aqeel to Patheon's
executive team, as his expertise and leadership within the industry is
truly remarkable" stated James C. Mullen, Patheon's Chief Executive Officer. "In his new role, Aqeel will be
focused on supporting the advancement of Patheon's recently acquired
business unit focused solely on proprietary products and technology."
"I am excited about the opportunity to move forward with the newly
combined company," commented Dr. Fatmi. "It has been an honor to be a
part of growing Banner's business over the last several years and I
look forward to playing a further role in developing the new vision and
strategy for the business."
Dr. Fatmi most recently served on Banner Pharmacaps' global leadership
team as Global Vice President, Research & Development and Operations.
In this role, he managed the development, registration, tech transfer
and launch of new and existing proprietary and customer products, as
well as the oversight of all of the company's production operations.
Dr. Fatmi was a founder of the Georgia Combinatorial Chemistry Center
at Georgia State University in Atlanta with a focus to discover small
molecule drugs for cancer, HIV and other infectious diseases. He spent
a major part of his career at Solvay Pharmaceuticals, where he served
as Senior Vice President of Research & Development, being responsible
for the development, approval and launch of new drugs.
Dr. Fatmi holds a Ph.D. in Medicinal Chemistry from The University of
Georgia, Athens. After graduation Dr. Fatmi was a National Science
Foundation Post Doctoral Fellow for one year at The University of
Georgia.
About Patheon Inc.
Patheon Inc. (TSX: PTI) is a leading provider of contract development
and commercial manufacturing services to the global pharmaceutical
industry for a full array of solid and sterile dosage forms. Through
the company's recent acquisition of Banner Pharmacaps - a market leader
in soft gelatin capsule technology - Patheon now also includes a
proprietary products and technology business.
Patheon provides the highest quality products and services to
approximately 300 of the world's leading pharmaceutical and
biotechnology companies. The company's integrated development and
manufacturing network consists of thirteen manufacturing facilities and
eleven development centers across North America and Europe. Patheon
enables customer products to be launched with confidence anywhere in
the world. For more information visit www.patheon.com.
SOURCE Patheon Inc.